<DOC>
	<DOCNO>NCT00002023</DOCNO>
	<brief_summary>To establish relationship oral dose zidovudine ( AZT ) hematologic toxicity . AZT preliminarily show decrease significant event death group AIDS / Pneumocystis carinii pneumonia ( PCP ) AIDS relate complex ( ARC ) patient follow time limited period . If data withstand follow-up , appear AZT potential antiretroviral agent may application use stage HIV disease . At time optimal dose cause significant toxicity know . If drug widespread application , become imperative study dose toxicity . Patients document HIV viremia well evaluate dose-escalating protocol toxicity , persistent viremia , evidence improvement immune dysfunction , development manifestation HIV disease . Drug level monitor correlate toxicity viremia .</brief_summary>
	<brief_title>An Oral Dose-Ranging Finding Study Patients With HIV Disease , CDC Classification Groups IIB , III , IV-C2</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must HIV reactivity . Patients must belong one follow three group accord CDC classification : IIB include patient autoimmune thrombocytopenia ( platelet count = &lt; 100000 platelets/mm3 ) . OR Lymphopenia ( lymphocyte count = &lt; 1000 cells/mm3 ) . OR Helper cell lymphopenia ( helper cell &lt; mean normal ) . OR CDC classification III IVC2 . Patients = &lt; involuntary 10 percent weight loss last 6 month . ECOG performance status 0 1 . Weigh 70 kg + 15 kg order standardize g/kg dosing . Positive antibody HIV ELISA test kit . If ELISA negative , eligibility confirm second confirmatory test , i.e. , immunoblot . Exclusion Criteria Coexisting Condition : Patients follow exclude : AIDS CDC classification stage IV except stage IVC2 . HIV antibody negative immunoblot . Persistent fever &gt; 38.5 degree C. Persistent diarrhea undiagnosed &gt; 1 month . Involuntary weight loss &gt; 10 percent 6 month prior study entry . ECOG performance status 2 , 3 , 4 . Class IVC2 prior history : Multidermal herpes zoster . Oral candidiasis one occasion . Tuberculosis . Concurrent Medication : Excluded : Other antiretroviral agent . Active immunomodulating agent . Any experimental therapy . Drugs cause anemia neutropenia . Drugs glucuronidated may interfere metabolism AZT , i.e. , acetaminophen &gt; 5 day . Acyclovir systemically administer &gt; 5 day . Any experimental agent . Patients follow exclude : AIDS CDC classification stage IV except stage IVC2 . HIV antibody negative immunoblot . Persistent fever &gt; 38.5 degree C. Persistent diarrhea undiagnosed &gt; 1 month . Involuntary weight loss &gt; 10 percent 6 month prior study entry . ECOG performance status 2 , 3 , 4 . Class IVC2 prior history : Multidermal herpes zoster . Oral candidiasis one occasion . Tuberculosis . Prior Medication : Excluded within 3 month study entry : Other antiretroviral agent . Active immunomodulating agent . Excluded within 2 week study entry : Drugs cause anemia neutropenia . Drugs glucuronidated may interfere metabolism zidovudine ( AZT ) , i.e. , acetaminophen &gt; 5 day . Acyclovir systemically administer &gt; 5 day . Any experimental agent . Known active drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1995</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>